Complement, Fc receptors and antibodies: a Trojan horse in HIV infection?
- PMID: 20048703
- DOI: 10.1097/COH.0b013e32832f0108
Complement, Fc receptors and antibodies: a Trojan horse in HIV infection?
Abstract
Purpose of review: Because complement is present in all fluids of the body, including serum, saliva and seminal fluid, and is found at mucosal surfaces and in the brain, all pathogens have to deal with complement proteins. Thus, immediately upon entering the host, independent on the route of infection, HIV activates the complement system. Although a first line of immune defense, complement cannot eliminate retroviral infections completely.
Recent findings: Recent data indicate that complement, in concert with non-neutralizing antibodies, contributes to the control of HIV replication at early stages of infection. In parallel or at later stages, complement and non-neutralizing antibodies may counteract the immune response by enhancing HIV infection via complement and Fc-receptor-positive cells in 'cis' and 'trans'.
Summary: This review highlights current knowledge in this field and emphasizes the contribution of complement and non-neutralizing antibodies in controlling versus and enhancing infection.
Similar articles
-
Fc receptor but not complement binding is important in antibody protection against HIV.Nature. 2007 Sep 6;449(7158):101-4. doi: 10.1038/nature06106. Nature. 2007. PMID: 17805298
-
Infection of human peripheral blood mononuclear cells by erythrocyte-bound HIV-1: effects of antibodies and complement.Virology. 2011 Apr 10;412(2):441-7. doi: 10.1016/j.virol.2011.01.037. Epub 2011 Feb 21. Virology. 2011. PMID: 21334707
-
Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35).Virology. 1996 Dec 1;226(1):13-21. doi: 10.1006/viro.1996.0623. Virology. 1996. PMID: 8941318
-
Neutralization and enhancement of in vitro and in vivo HIV and simian immunodeficiency virus infections.AIDS. 1990;4 Suppl 1:S151-62. AIDS. 1990. PMID: 2152561 Review.
-
Humoral immunity to HIV-1: neutralization and beyond.J Intern Med. 2007 Jul;262(1):5-25. doi: 10.1111/j.1365-2796.2007.01819.x. J Intern Med. 2007. PMID: 17598812 Review.
Cited by
-
On the meaning of affinity limits in B-cell epitope prediction for antipeptide antibody-mediated immunity.Adv Bioinformatics. 2012;2012:346765. doi: 10.1155/2012/346765. Epub 2012 Nov 14. Adv Bioinformatics. 2012. PMID: 23209458 Free PMC article.
-
Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent.J Virol. 2013 Jan;87(1):273-81. doi: 10.1128/JVI.01640-12. Epub 2012 Oct 17. J Virol. 2013. PMID: 23077299 Free PMC article.
-
A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro.PLoS One. 2012;7(7):e41235. doi: 10.1371/journal.pone.0041235. Epub 2012 Jul 23. PLoS One. 2012. PMID: 22844444 Free PMC article.
-
Dengue virus activates polyreactive, natural IgG B cells after primary and secondary infection.PLoS One. 2011;6(12):e29430. doi: 10.1371/journal.pone.0029430. Epub 2011 Dec 22. PLoS One. 2011. PMID: 22216280 Free PMC article.
-
Immune-based approaches to the prevention of mother-to-child transmission of HIV-1: active and passive immunization.Clin Perinatol. 2010 Dec;37(4):787-805, ix. doi: 10.1016/j.clp.2010.08.005. Clin Perinatol. 2010. PMID: 21078451 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials